Company news
Halberd Corp. (OTC:HALB) news
Halberd Corp. news releases on 6ix. Latest, Nov 2, 2021: GTX Corp Begins Selling Vita-Shield-Max Immune Support Nutraceutical
Press releases — page 3
GTX Corp Begins Selling Vita-Shield-Max Immune Support Nutraceutical
November 2, 2021
Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease
October 31, 2021
Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer's Disease
October 31, 2021
Halberd Files Provisional Patent on Breakthrough Obesity Treatment
October 24, 2021
Halberd's PTSD/Alzheimer's R&D Reveals Link to Potential Obesity Cure
October 19, 2021
Halberd and GTX Corp Sign Scientific Collaboration and Reseller Agreement
October 11, 2021
Halberd and GTX Corp. Sign Scientific Collaboration and Reseller Agreement
October 11, 2021
Halberd Corporation CEO Letter
October 6, 2021
Halberd's VITASHIELDMAX(TM) Immunity Support Product Available on Amazon
October 4, 2021
Halberd and heliosDX of RushNet Enter Scientific Collaboration Agreement
September 21, 2021
Halberd's Treatment Eradicates Primary Building Block of Alzheimer’s Disease
September 12, 2021
Halberd Corporation Appoints Anthony Mirabelli Vice-President, Mergers & Acquisitions
September 7, 2021
Halberd Corporation Alzheimer's Disease Treatment Tests Yield Outstanding Results
August 29, 2021
Halberd Receives Patent for Treatment of Cockayne Syndrome - May Provide Pathway to Slow Aging
August 24, 2021
Halberd Files Provisional Patent Application - Furthering Efforts on Alzheimer's Disease
August 22, 2021
Halberd Corp. VITA-SHIELD-MAX(TM) Available - Buy Now!
August 17, 2021
Halberd's Disease Elimination Technology R&D at Youngstown State University (YSU) Draws Attention of CBS Affiliate WKBN
August 15, 2021
Halberd’s Disease Elimination Technology R&D at Youngstown State University (YSU) Draws Attention of CBS Affiliate WKBN
August 15, 2021
Halberd Corporation Adds Blood-Borne Disease Treatment Capability with Addition of Noted Nephrologist
August 10, 2021
Halberd Corporation Adds Blood-Borne Disease Treatment Capability With Addition Of Noted Nephrologist
August 10, 2021
Halberd Corporation's VITA-SHIELD-MAX(TM) Immunity Support Product Shipped
August 8, 2021
Halberd Corporation Successfully Establishes Disease Eradication Proof-of-Concept - "Never Before Accomplished"
July 27, 2021
Halberd Corp. Advances the Elimination of Antigens Present in Alzheimer's Disease & PTSD/Chronic Traumatic Encephalopathy
July 21, 2021
Halberd Corp. Advances the Elimination of Antigens Present in Alzheimer’s Disease & PTSD/Chronic Traumatic Encephalopathy
July 21, 2021
Halberd Corp. Discovers a Proprietary Disease-Causing Antigen Removal Process
June 29, 2021
Halberd Corporation's Proprietary Technology for Alzheimer's Disease Enters Stage 4 of 7 Stage Process
June 20, 2021
Halberd Corporation's Proprietary Technology for Alzheimer’s Disease Enters Stage 4 of 7 Stage Process
June 20, 2021
Halberd Corporation Successfully Conjugates Metallic Particles and Antibodies Against Alzheimer's Disease-Associated Antigens
June 15, 2021
Halberd Corporation Undertakes Process Toward the Elimination of Alzheimer's Disease
June 8, 2021
Halberd Corporation Undertakes Process Toward the Elimination of Alzheimer’s Disease
June 8, 2021
Halberd Corporation Creates Two New and Stronger SARS-CoV-2 Neutralizing Antibodies
June 6, 2021
Halberd Corp. Files Provisional Patent Application Complementing Patented Extracorporeal Radio Frequency/Laser Projects
May 31, 2021
Halberd Corporation Successfully Conjugates Metallic Particles and E. Coli Antibody
May 24, 2021
"MarketWatch" Features Halberd Corporation With Prominent Pharmaceutical Companies on New Treatments for COVID-19
May 18, 2021
Halberd Corporation Reports Successful Conjugation of Metallic Particles & SARS-CoV-2 Proprietary Monoclonal Antibody
May 16, 2021
Halberd Corporation Begins Testing of Patented Process for Laser Eradication of Disease
May 12, 2021
Halberd Corp. Designated as a BREAKOUT Stock to Watch in Investor Publications
May 9, 2021
Halberd Corporation Appoints New Chief Technical Officer to Optimize Upcoming Experiments On Radio Frequency and Laser Eradication of Disease
May 3, 2021
Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Treating and Curing Covid-19 Infection Utilizing a Laser
April 25, 2021
Halberd Antibodies Shown To Be Effective Against Multiple Covid-19 Mutations
April 20, 2021
Halberd Corporation Moves Radio Frequency (RF) Disease Elimination Effort Forward with the Addition of Youngstown State University (YSU) and Dr. William G. Sturrus
April 18, 2021
Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Covid-19 Inflammatory Cytokine Storm Treatment
April 11, 2021
Halberd Corporation's Scientific Breakthrough: Conjugating Metallic Particles to SARS-CoV-2 and E. Coli Antigens
March 29, 2021
Halberd Corporation Completes Compilation of Medical Articles in Support of Nutraceuticals in Their VITA-SHIELD-MAX(TM) Immune Booster
March 22, 2021
Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application Covering Extracorporeal Treatment of COVID-19 and Other Medical Maladies
March 17, 2021
Halberd Corporation Starts VITA-SHIELD-MAX(TM) Immunity Boosting Nutraceutical Production
March 15, 2021
Halberd Corporation Files VITA-SHIELD-MAX(TM) Trademark for Immunity Boosting Nutraceutical
March 10, 2021
Halberd Corporation's CEO Interviewed on "The Stock Day Podcast" - Focus on Halberd's New 20x Affinity Neutralizing SARS-COV-2 Antibody
March 8, 2021
Halberd's 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater
March 1, 2021
Halberd Collaborates with GreenBioAZ, Inc. for the Development of its Patent Pending Radio Frequency Technology to Eliminate Disease Pathogens
February 15, 2021